🎉 M&A multiples are live!
Check it out!

Elutia Valuation Multiples

Discover revenue and EBITDA valuation multiples for Elutia and similar public comparables like Cynata Therapeutics, Mesoblast, and Aroa Biosurgery.

Elutia Overview

About Elutia

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women’s Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.


Founded

2015

HQ

United States of America
Employees

51

Website

aziyo.com

Financials

LTM Revenue $26.9M

LTM EBITDA -$12.9M

EV

$93.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Elutia Financials

Elutia has a last 12-month revenue of $26.9M and a last 12-month EBITDA of -$12.9M.

In the most recent fiscal year, Elutia achieved revenue of $24.4M and an EBITDA of -$45.9M.

Elutia expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Elutia valuation multiples based on analyst estimates

Elutia P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $24.7M $24.4M XXX XXX XXX
Gross Profit $19.2M $11.1M XXX XXX XXX
Gross Margin 78% 45% XXX XXX XXX
EBITDA -$31.7M -$45.9M XXX XXX XXX
EBITDA Margin -128% -188% XXX XXX XXX
Net Profit -$32.9M -$37.7M XXX XXX XXX
Net Margin -133% -154% XXX XXX XXX
Net Debt $7.3M $4.4M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Elutia Stock Performance

As of April 15, 2025, Elutia's stock price is $2.

Elutia has current market cap of $82.1M, and EV of $93.6M.

See Elutia trading valuation data

Elutia Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$93.6M $82.1M XXX XXX XXX XXX $-1.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Elutia Valuation Multiples

As of April 15, 2025, Elutia has market cap of $82.1M and EV of $93.6M.

Elutia's trades at 3.5x LTM EV/Revenue multiple, and -7.3x LTM EBITDA.

Analysts estimate Elutia's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Elutia and 10K+ public comps

Elutia Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $93.6M XXX XXX XXX
EV/Revenue 3.8x XXX XXX XXX
EV/EBITDA -2.0x XXX XXX XXX
P/E -1.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -4.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Elutia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Elutia Valuation Multiples

Elutia's NTM/LTM revenue growth is 45%

Elutia's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, Elutia's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Elutia's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Elutia and other 10K+ public comps

Elutia Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -1% XXX XXX XXX XXX
EBITDA Margin -188% XXX XXX XXX XXX
EBITDA Growth 45% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -143% XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue 51% XXX XXX XXX XXX
G&A Expenses to Revenue 77% XXX XXX XXX XXX
R&D Expenses to Revenue 16% XXX XXX XXX XXX
Opex to Revenue 144% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Elutia Public Comps

See public comps and valuation multiples for Regenerative Medicine and Medical Devices comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Elutia M&A and Investment Activity

Elutia acquired  XXX companies to date.

Last acquisition by Elutia was  XXXXXXXX, XXXXX XXXXX XXXXXX . Elutia acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Elutia

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Elutia

When was Elutia founded? Elutia was founded in 2015.
Where is Elutia headquartered? Elutia is headquartered in United States of America.
How many employees does Elutia have? As of today, Elutia has 51 employees.
Who is the CEO of Elutia? Elutia's CEO is Dr. C. Randal Mills, PhD.
Is Elutia publicy listed? Yes, Elutia is a public company listed on NAS.
What is the stock symbol of Elutia? Elutia trades under ELUT ticker.
When did Elutia go public? Elutia went public in 2020.
Who are competitors of Elutia? Similar companies to Elutia include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of Elutia? Elutia's current market cap is $82.1M
What is the current revenue of Elutia? Elutia's last 12-month revenue is $26.9M.
What is the current EBITDA of Elutia? Elutia's last 12-month EBITDA is -$12.9M.
What is the current EV/Revenue multiple of Elutia? Current revenue multiple of Elutia is 3.5x.
What is the current EV/EBITDA multiple of Elutia? Current EBITDA multiple of Elutia is -7.3x.
What is the current revenue growth of Elutia? Elutia revenue growth between 2023 and 2024 was -1%.
Is Elutia profitable? Yes, Elutia is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.